These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 34702339)
1. Therapeutic activity of sarpogrelate and dopamine D Fouad Shalaby MA; Abd El Latif HA; El Yamani M; Galal MA; Kamal S; Sindi I; Masaood R BMC Pharmacol Toxicol; 2021 Oct; 22(1):64. PubMed ID: 34702339 [TBL] [Abstract][Full Text] [Related]
2. Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats. Fouad Shalaby M; Latif HAAE; Yamani ME; Galal MA; Kamal S; Sindi I Curr Ther Res Clin Exp; 2021; 95():100647. PubMed ID: 34777640 [TBL] [Abstract][Full Text] [Related]
4. Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy. Kobayashi S; Satoh M; Namikoshi T; Haruna Y; Fujimoto S; Arakawa S; Komai N; Tomita N; Sasaki T; Kashihara N Clin Exp Nephrol; 2008 Apr; 12(2):119-125. PubMed ID: 18175064 [TBL] [Abstract][Full Text] [Related]
5. Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats. Moro M; Inada Y; Miyata H; Komatsu H; Kojima M; Tsujii H Clin Exp Pharmacol Physiol; 2001 Aug; 28(8):651-8. PubMed ID: 11473532 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus. Kabir MT; Ferdous Mitu J; Akter R; Akhtar MF; Saleem A; Al-Harrasi A; Bhatia S; Rahman MS; Damiri F; Berrada M; Rahman MH Environ Sci Pollut Res Int; 2022 Jul; 29(31):46385-46404. PubMed ID: 35486279 [TBL] [Abstract][Full Text] [Related]
7. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats. Miyagi M; Itoh F; Taya F; Arai N; Isaji M; Kojima M; Ujiie A Biol Pharm Bull; 1996 Sep; 19(9):1210-3. PubMed ID: 8889042 [TBL] [Abstract][Full Text] [Related]
9. Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats. Umrani DN; Bodiwala DN; Goyal RK Mol Cell Biochem; 2003 Jul; 249(1-2):53-7. PubMed ID: 12956398 [TBL] [Abstract][Full Text] [Related]
10. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Rains CP; Bryson HM; Fitton A Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332 [TBL] [Abstract][Full Text] [Related]
11. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Krysiak R; Okopien B Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447 [TBL] [Abstract][Full Text] [Related]
12. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline. Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770 [TBL] [Abstract][Full Text] [Related]
13. Effects of gallic acid on hemodynamic parameters and infarct size after ischemia-reperfusion in isolated rat hearts with alloxan-induced diabetes. Ramezani-Aliakbari F; Badavi M; Dianat M; Mard SA; Ahangarpour A Biomed Pharmacother; 2017 Dec; 96():612-618. PubMed ID: 29035826 [TBL] [Abstract][Full Text] [Related]
14. Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes. Tavares G; Marques D; Barra C; Rosendo-Silva D; Costa A; Rodrigues T; Gasparini P; Melo BF; Sacramento JF; Seiça R; Conde SV; Matafome P Mol Metab; 2021 Sep; 51():101241. PubMed ID: 33933677 [TBL] [Abstract][Full Text] [Related]
16. Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. Brasil D; Temsah RM; Kumar K; Kumamoto H; Takeda N; Dhalla NS J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):53-9. PubMed ID: 12000979 [TBL] [Abstract][Full Text] [Related]
17. Renal injury induced in alloxan diabetic rats. Role of Mycophenolate Mofetil as therapeutic agent. Elseweidy MM; Elswefy SE; Ali AE; Shawky M Pathol Res Pract; 2014 Dec; 210(12):979-84. PubMed ID: 24939145 [TBL] [Abstract][Full Text] [Related]
18. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Webster J Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691 [TBL] [Abstract][Full Text] [Related]
19. The regulatory effect of bromocriptine on cardiac hypertrophy by prolactin and D2 receptor modulation. Aguayo-Cerón KA; Calzada-Mendoza CC; Méndez-Bolaina E; Romero-Nava R; Ocharan-Hernández ME Clin Exp Hypertens; 2020 Oct; 42(7):675-679. PubMed ID: 32478610 [TBL] [Abstract][Full Text] [Related]
20. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. Ohta K; Kuno S; Mizuta I; Fujinami A; Matsui H; Ohta M Life Sci; 2003 Jun; 73(5):617-26. PubMed ID: 12770616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]